Highly Innovative Drug Program in the Czech Republic: Description and Pharmacoeconomic Results—Cost-Effectiveness and Budget Impact Analyses
ConclusionsThis analysis provides better insight into the HID program for costly innovative drugs over a 10-year follow-up. A successful transition to PR status was observed for most of the HIDs (83%). (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - October 10, 2018 Category: International Medicine & Public Health Source Type: research
Cost Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia
ConclusionsWith lower costs, higher response rates, and comparable QALYs, DTG + ABC/3TC can be considered as a cost-effective alternative. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - October 5, 2018 Category: International Medicine & Public Health Source Type: research
Antirheumatic Prescribing Patterns and Direct Medicine Costs in the South African Private Health Sector
ConclusionsThe direct medicine treatment cost of RA in the South African private health sector is driven by the high volume of DMARDs and the high mean costs of biologics, particularly adalimumab. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - September 17, 2018 Category: International Medicine & Public Health Source Type: research
The State of Health Technology Assessment in the Ethiopian Health Sector: Learning from Recent Policy Initiatives
Publication date: September 2018Source: Value in Health Regional Issues, Volume 16Author(s): Elias Asfaw Zegeye, Abduljelli Reshad, Eyersualem Animut Bekele, Belay Aurgessa, Zenebech GellaABSTRACTHealth technology assessment (HTA) has previously been implemented only in a fragmented manner in the Ethiopian health sector decision-making cycle, and the sector has been hampered by limited institutional capacity and skilled human resources to inform evidence-based decision making. The country is in the midst of widescale implementation of a community-based health insurance scheme and is preparing for the launch of a social hea...
Source: Value in Health Regional Issues - September 7, 2018 Category: International Medicine & Public Health Source Type: research
Drug Policy in Greece
ConclusionsThe pricing and reimbursement decision-making processes are centralized under the competence of the MoH. Despite the good intentions of the reformers, there are still some aspects of transparency, equity, and long-term sustainability that remain under question in Greece. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - September 7, 2018 Category: International Medicine & Public Health Source Type: research
Pharmacoeconomics Evaluations of Oral Anticancer Agents: Systematic Review of Characteristics, Methodological Trends, and Reporting Quality
ConclusionsHigh heterogeneity in methods in studies may limit the robustness and transferability of results, potentially misleading decision makers toward wrong decisions on OACDs. The transferability and generalizability of results are further limited by a “less than ideal” adherence to current reporting standards. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - August 23, 2018 Category: International Medicine & Public Health Source Type: research
HTA and Its Use in Drug Policies: Singapore
ConclusionTo achieve greater impact, Singapore needs to expand its HTA capacity beyond subsidy decision making and drive appropriate care in a sustainable manner for future generations. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
Smoking Behavior among Jordanians: Physical, Psychological, Social, and Economic Reasons
ConclusionsWomen were more likely to smoke for physical factors that are positively correlated with the price of cigarettes, rendering them less responsive to an increase in the price of cigarettes. Conversely, men were more likely to smoke for social reasons that are negatively correlated with the price of cigarettes; thus, men are more responsive to an increase in the price of cigarettes. Future public policies aiming to combat smoking in Jordan should consider sex differences in smoking behavior because one policy may not necessarily fit all. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
Return on Investment Analysis of Breast Cancer Screening and Downstaging in Egypt: Implications for Developing Countries
ConclusionsBreast cancer represents an increasing burden on health care in Egypt and other developing countries. This study concludes that a community-based downstaging program resulted in a positive ROI, or overall cost-savings. The findings inform that policymakers in low-income and middle-income countries may consider implementing community-based downstaging programs for breast cancer. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
Optimization Approach for Estimating the Required Amount of Pharmaceuticals in the Russian Federation
ConclusionsThe proposed algorithm for estimating the amount of medicines can be successfully used by both pharmaceutical (or dealer) companies and government agencies for objective population provision. The usual sources of such estimates are based either on market surveys or on pharmacy network data. Both ways are very expensive and do not allow predicting mass demand in the future, for example, with an unexpected epidemic or the emergence of new medicines. In addition, the proposed algorithm can be successfully applied to the pricing problem: a variation in price may show a change in the volume of use. (Source: Value in ...
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
Drug Policy in Romania
ConclusionsThe drug policy in Romania is centered on price reduction using different techniques and no value-based criteria are used. The pricing is not included in the health technology assessment system, managed entry agreements are not used, and the main effect visible at the patient level is the lack of drugs for some therapeutic areas. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
Drug Policy in Estonia
Publication date: September 2018Source: Value in Health Regional Issues, Volume 16Author(s): Kadri Mägi, Marika Lepaste, Monika Szkultecka-DębekAbstractThe aim of this article was to present a general overview of the health care system as well as pricing and reimbursement environment in Estonia. In Estonia the main stakeholders in the pharmaceutical sector are the Ministry of Social Affairs, the State Agency of Medicine, and the Estonian Health Insurance Fund. The national health insurance scheme is public, and approximately 95% of the population is covered by it. It is a social insurance, and universal and equal access ...
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
Treatment Satisfaction Questionnaire for Medication: Validation of the Translated Arabic Version among Patients Undergoing Warfarin Therapy in Saudi Arabia
ConclusionsThis study provides evidence in favor of the reliability and validity of the Arabic version of TSQM 1.4 as a useful measure of satisfaction with anticoagulant therapy in patients visiting ACCs. The TSQM subscales in this patient setting seem to detect a clinically meaningful change over time, enhancing the potential of their use in routine practice. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
An Evidence Framework for Off-Patent Pharmaceutical Review (EFOR) for Health Technology Assessment in Emerging Markets
ConclusionsEmerging countries have a significant need for an HTA tool that balances affordability with accurate evidence showing the value differentiation of OPPs. The value attributes in this setting often are different from those in developed markets, which emphasize new products and have high regulation and manufacturing standards. The EFOR is an easy-to-use, adaptable framework that emerging countries can use to increase the consistency, transparency, and effectiveness of drug decision making. The open source EFOR is available as Supplemental Materials. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
Managed Entry Agreements for Pharmaceutical Products in Middle East and North African countries: Payer and Manufacturer Experience and Outlook
ConclusionsFew MENA countries are implementing MEAs, which could be due to lack of data infrastructure as well as a shortage of experts in health economics. Health care stakeholders continue to be optimistic regarding the potential of MEA implementation. (Source: Value in Health Regional Issues)
Source: Value in Health Regional Issues - July 10, 2018 Category: International Medicine & Public Health Source Type: research
